The Danish biotechnology company Zealand Pharma A/S has appointed Frank Sanders as president of its US operations. Mr Sanders joins Zealand from Sage Therapeutics Inc, where he was general manager of the US commercial team. He previously worked in senior commercial roles at Janssen Pharmaceuticals and GlaxoSmithKline Plc. Mr Sanders holds a degree in business administration from Wittenberg University in Ohio, US. Zealand Pharma develops peptide-based medicines for metabolic and gastrointestinal diseases, and is planning to launch four potential products starting in 2021.
Zealand Pharma announced the appointment on 15 June 2020.
Copyright 2020 Evernow Publishing Ltd